Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits.
Amber Bio has raised $26.0M in total funding. The most recent round was Seed. The last funding was announced in August 2023.
Amber Bio's investors include Andreessen Horowitz, SV Angel, Eli Lilly, Hummingbird Ventures, Playground Global.
Amber Bio is headquartered in San Francisco, United States.
Amber Bio is a biotechnology company pioneering new gene editing modalities using multi-kilobase edits.
Amber Bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amber Bio — Funding & Investors." VCBacked, August 3, 2023, https://www.vcbacked.co/company/amber-bio. Accessed July 20, 2026.
VCBacked. (2023). Amber Bio — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/amber-bio
{{cite web |title=Amber Bio — Funding & Investors |url=https://www.vcbacked.co/company/amber-bio |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated